SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-086697
Filing Date
2022-08-05
Accepted
2022-08-05 16:11:09
Documents
14
Period of Report
2022-08-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2222653d1_8k.htm   iXBRL 8-K 28618
2 EXHIBIT 10.1 tm2222653d1_ex10-1.htm EX-10.1 11254
3 EXHIBIT 10.2 tm2222653d1_ex10-2.htm EX-10.2 10463
  Complete submission text file 0001104659-22-086697.txt   229652

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20220802.xsd EX-101.SCH 3039
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20220802_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20220802_pre.xml EX-101.PRE 22599
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2222653d1_8k_htm.xml XML 3614
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 221140916
SIC: 2836 Biological Products, (No Diagnostic Substances)